Home / OIF News / Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in OI

Share

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in OI

October 7, 2024

Print Version

Ultragenyx-Color-Logo

The OI Foundation would like to bring your attention to an update from Ultragenyx!

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

CLICK HERE TO VIEW THE PRESS RELEASE